| Autor: |
Chtiba N; Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Cherif D; Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Mersni I; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Kadri M; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Jemei A; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Lassoued I; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia., Razgallah Khrouf M; Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.; Directorate of Pharmacy and Medicines, Ministry of Health, Tunis, Tunisia. |
| Abstrakt: |
Given the unstoppable spread of coronavirus disease (COVID-19), the development of a vaccine was needed to contain the pandemic. In such a situation of global emergency, regulatory authorities ensured timely, safe, and equitable access to the vaccine.This article aims to outline the roles of the Tunisian regulatory authority, the Directorate of Pharmacy and Medicines (DPM) at the Ministry of Health, in registration and procurement of the COVID-19 vaccine.Requirement to grant the Exceptional Provisional Authorizations of Marketing (EPAM) for COVID-19 vaccines was 27 days versus 869 days for conventional marketing authorizations (MAs). The DPM has optimized its activity through: early dialogue with manufacturers, online submission, the use of distance communication technologies. It has demonstrated unprecedented flexibility through the continuous and rolling review approach.Regulatory authorities in Tunisia and around the world have partnered with manufacturers to speed up administrative procedures while ensuring the quality, safety, and efficacy of vaccines. |
